This is the classic website, which will be retired eventually. Please visit the modernized instead.

Key Record Dates Identifier: NCT05687266
Brief Title: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

First Submitted : December 28, 2022
First Submitted that Met QC Criteria : January 17, 2023
First Posted : January 18, 2023

Last Update Submitted that Met QC Criteria : February 2, 2024
Last Update Posted : February 6, 2024